What is PepGen Profitability Rank?
PepGen has the Profitability Rank of 2. It has had trouble to make a profit.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1.
Operating Margin %
2.
Piotroski F-Score
3. Trend of the
Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
PepGen's Operating Margin % for the quarter that ended in Mar. 2024 was %. As of today, PepGen's Piotroski F-Score is 3.
Competitive Comparison of PepGen's Profitability Rank
For the Biotechnology subindustry, PepGen's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PepGen's Profitability Rank Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PepGen's Profitability Rank distribution charts can be found below:
* The bar in red indicates where PepGen's Profitability Rank falls into.
PepGen Profitability Rank Calculation
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
PepGen has the Profitability Rank of 2. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
1. Operating Margin %
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
PepGen's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2. Piotroski F-Score
Warning Sign:
Piotroski F-Score of 3 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
PepGen has an F-score of 3. It is a bad or low score, which usually implies poor business operation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
PepGen (PepGen) Business Description
Traded in Other Exchanges
N/A
Address
321 Harrison Avenue, 8th Floor, Boston, MA, USA, 02118
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
Executives
| James G Mcarthur |
director, officer: President and CEO |
NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453 |
| Jaya Goyal |
officer: See Remarks |
PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142 |
| Habib J Dable |
director |
C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139 |
| James E Flynn |
10 percent owner, other: *Possible Member of 10% Group |
780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
| Ra Capital Healthcare Fund Lp |
director, 10 percent owner |
200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
| Laurie Keating |
director |
300 THIRD STREET, CAMBRIDGE MA 02142 |
| Christopher Ashton |
director |
PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142 |
| Deerfield Management Company, L.p. (series C) |
10 percent owner, other: *Possible Member of 10% Group |
345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010 |
| Michelle L Mellion |
officer: See Remarks |
PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142 |
| Noel Donnelly |
officer: Chief Financial Officer |
PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142 |
| Niels Svenstrup |
officer: See Remarks |
PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142 |
| Sonia Bracegirdle |
officer: See Remarks |
PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142 |
| Deerfield Mgmt V, L.p. |
10 percent owner, other: *Possible Member of 10% Group |
345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010 |
| Deerfield Private Design Fund V, L.p. |
10 percent owner, other: *Possible Member of 10% Group |
780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
| Oxford Science Enterprises Plc |
10 percent owner |
46 WOODSTOCK ROAD, OXFORD X0 OX2 6HT |
PepGen (PepGen) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PEPG has been successfully added to your